ROSELLINI, MATTEO
 Distribuzione geografica
Continente #
EU - Europa 261
NA - Nord America 248
AS - Asia 46
AF - Africa 32
Totale 587
Nazione #
US - Stati Uniti d'America 245
IT - Italia 76
SE - Svezia 61
CI - Costa d'Avorio 29
IE - Irlanda 28
CH - Svizzera 23
DE - Germania 23
IN - India 21
JO - Giordania 17
BG - Bulgaria 13
FI - Finlandia 11
GB - Regno Unito 10
CN - Cina 5
RU - Federazione Russa 5
FR - Francia 4
CA - Canada 3
NL - Olanda 3
TG - Togo 3
AT - Austria 2
HK - Hong Kong 2
PL - Polonia 2
JP - Giappone 1
Totale 587
Città #
Chandler 40
Abidjan 29
Dublin 28
Bern 22
Amman 17
Ashburn 16
Bologna 15
Sofia 13
Helsinki 11
Turin 11
Fairfield 10
Princeton 10
Southend 9
Berlin 5
Redmond 5
San Polo di Torrile 5
Boydton 4
Bühl 4
Florence 4
Milan 4
Cambridge 3
Columbus 3
Lomé 3
Paris 3
Rome 3
San Diego 3
Telgate 3
Amsterdam 2
Ann Arbor 2
Boardman 2
Gatineau 2
Genoa 2
Hong Kong 2
Hyderabad 2
Moscow 2
Norwalk 2
Seattle 2
Warsaw 2
Bangalore 1
Beijing 1
Cedar Knolls 1
Des Moines 1
Houston 1
London 1
Los Angeles 1
Lugano 1
New York 1
Padova 1
Redwood City 1
Shijiazhuang 1
Tokyo 1
Toronto 1
Trento 1
Vienna 1
Woodbridge 1
Totale 322
Nome #
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 58
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 46
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 40
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 37
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 31
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 31
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 29
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 26
Bone targeting agents in patients with metastatic prostate cancer: State of the art 26
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 25
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 21
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 20
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 19
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 17
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 16
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 14
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 14
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 13
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 13
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 12
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 11
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 10
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 10
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 10
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 9
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 9
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 9
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 8
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 8
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 8
Current androgen receptor antagonists under investigation for resistant prostate cancer 8
Treating prostate cancer by antibody-drug conjugates 8
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 7
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 7
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 7
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 6
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 5
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 2
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 1
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 1
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 1
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 1
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 1
Totale 655
Categoria #
all - tutte 3.214
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.214


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 7 0 5
2021/202292 0 0 1 3 2 1 8 21 6 3 33 14
2022/2023365 5 15 7 17 36 35 21 19 95 11 55 49
2023/2024186 19 36 21 14 18 27 7 17 13 14 0 0
Totale 655